© 2020 PrimeVax Immuno-Oncology

PrimeVax

Investor Relations

PrimeVax is a clinical stage biotechnology company with our first indication for PD-1 failed melanoma. We opened our first IND with the FDA and are currently mobilizing our clinical trial sites. A non-confidential slide deck may be provided for potential partnership contacts. 

 

For business development inquiries, please email:

investorrelations@primevax.com